Massachusetts Financial Services Co. MA Has $1.94 Billion Stock Holdings in AbbVie Inc. $ABBV

Massachusetts Financial Services Co. MA decreased its stake in AbbVie Inc. (NYSE:ABBV) by 3.0% in the third quarter, Holdings Channel reports. The institutional investor owned 8,361,387 shares of the company’s stock after selling 258,984 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in AbbVie were worth $1,935,996,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Conning Inc. raised its holdings in shares of AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after purchasing an additional 12,690 shares in the last quarter. Diversified Trust Co boosted its holdings in AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after purchasing an additional 10,891 shares in the last quarter. Dohj LLC increased its position in AbbVie by 41.8% during the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after buying an additional 1,335 shares during the last quarter. Permanent Capital Management LP bought a new position in AbbVie during the third quarter valued at about $720,000. Finally, Railway Pension Investments Ltd boosted its stake in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after acquiring an additional 211,800 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of AbbVie stock opened at $214.38 on Friday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market capitalization of $378.89 billion, a PE ratio of 162.41, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. The company’s fifty day moving average price is $226.80 and its two-hundred day moving average price is $216.47.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the business posted $3.00 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ABBV shares. Morgan Stanley upped their price objective on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Bank of America boosted their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Evercore ISI raised their target price on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $247.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.